2014-11-26 23:03:10 UTC

CGH Podcast November 2014: Mesalamine Dosage and Fecal Calprotectin in Patients With Quiescent Ulcerative Colitis

A study in the November issue of CGH investigated whether increasing doses of mesalamine reduces concentrations of fecal calprotectin in patients with quiescent ulcerative colitis. Dr. Kuemmerle speaks to co-author Dr. James Lewis of the Perelman School of Medicine at the University of Pennsylvania; Plus, summaries of top stories from this month's issue of GI and Hepatology News.

 

 

Osterman MT, Aberra FN, Cross R. Mesalamine Dose Escalation Reduces Fecal Calprotectin in Patients With Quiescent Ulcerative Colitis. Clinical Gastroenterology & Hepatology 2014; November 12(11): 1887–1893.e3
Abstract

 

 

 

Duration: 15.20m
Filetype: mp3
Bitrate: 96 KBPS
Frequency: 44100 HZ

 

 

More on Ulcerative Colitis

Association Between Low Trough Levels of Vedolizumab During Induction Therapy for Inflammatory Bowel Diseases and Need for Additional Doses Within 6 Months

Oct. 22, 2017

We investigated whether serum trough levels of vedolizumab, during the induction phase can determine whether patients need additional doses within 6 months.

How Will Translational Advances in Pediatric IBD Affect Practices?

Oct. 17, 2017

Dr. Rosen will discuss how new findings can make a difference for pediatric IBD patients at the Crohn’s & Colitis Congress.

Blog: Special 15th Anniversary Collection from Clinical Gastroenterology and Hepatology

Oct. 11, 2017

Celebrate this milestone with a look back at landmark articles, commentaries and reviews. Read more on the AGA Journals blog.